Hormone Therapy

A small cohort of adolescents and young adults who identify as transgender reported limited baseline knowledge of reproduction and expressed underlying reproductive concerns that may manifest as disinterest in becoming a parent, according to findings from a pilot study published in Transgender Health.

Nondiscrimination policies appeared associated with a decrease or no change in suicidality among gender minority individuals living in states with these policies, according to results of a cohort study published in JAMA Psychiatry.

Among a large cohort of Canadian women, premature menopause and current use of hormone therapy were associated with self-reported depression, according to results from a study published in Menopause.

Among a large cohort of transgender adults prescribed gender-affirming hormones, higher levels of cross-sex hormones did not increase the odds of hypertension, and hypertension diagnoses were fewer among transgender women who were ever prescribed progestins, according to data published in Transgender Health.

Prader-Willi syndrome, a neurodevelopmental disorder that occurs in about 1 in 15,000 births, is the most common genetic cause of life-threatening childhood obesity, which is just one of its complex symptoms. Still, it has proved extremely difficult to treat. Fortunately for the Prader-Willi syndrome community, researchers continue to test potential therapies to find a comprehensive treatment or a way to curb the most severe symptoms.

Androgen suppression therapy for prostate cancer, although effective, is associated with a host of systemic adverse effects.

Many adolescents who identify as transgender or gender nonconforming were identified as experiencing psychological comorbidities, such as depression, anxiety and suicidal ideation, with a greater burden observed among transgender males vs. transgender females, according to findings accepted for presentation at the Endocrine Society Annual Meeting.

The addition of apalutamide to androgen deprivation therapy provided a subsequent PFS benefit for men with nonmetastatic castration-resistant prostate cancer, according to results of a post-hoc analysis of the randomized phase 3 TITAN study presented at Genitourinary Cancers Symposium.

Several states across the country have introduced or are considering legislation that would prohibit medical treatment for children who may be transgender, including the use of pubertal blockers, a trend that has alarmed clinicians who say such bills reflect widespread misunderstandings and go against evidence-based practices.

In a large prospective cohort of postmenopausal women, those who had ever had hypothyroidism — whether treated with levothyroxine or not — were less likely to develop breast cancer than those without hypothyroidism, and the relationship was more pronounced among those who did not also use menopausal hormone therapy, according to findings published in Thyroid.